Blood Thinners & Anti-Obesity Shots Dominate Medicare Drug Spending From diabetes injectables to blockbuster blood thinners, a handful of drugs account for a sizable share

A MARKETING BOON FOR GLP-1 DRUGS: “Astounding” – 70% of Americans Have Obesity by New, More Accurate Definition. Weirdly, more people need blood pressure drugs

We came across a bullish thesis on Novo Nordisk A/S on The Analyst’s Journal’s Substack by A_Capital. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk

It takes a very particular kind of political brainworm to look at a country where nearly half the population is obese, where Medicare and Medicaid

SCIENCE: Study finds GLP-1 drugs may help prevent risks from sleep apnea.

Shutterstock GLP-1 drugs such as Ozempic have been shown to be extremely effective at helping diabetics manage their blood sugar, and almost anyone else to

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we talk

As demand for products scented like vanilla, pistachio and other edible indulgences soars, some GLP-1 users say there’s a link to their changed eating habits.

A comparative effectiveness study of glucose-lowering drugs finds the GLP-1 receptor agonists most protective against cardiovascular events, followed by SGLT2i and two older drug classes.

More and more workers are using weight loss drugs. It’s costing their employers a fortune  CNN Ozempic for All  The Atlantic Lopez: Expanding access to anti-obesity drugs

As pharma companies and President Trump tout initiatives to sell branded medications directly to cash-paying consumers, some entrepreneurs have seized on a potential business opportunity

Beata Zawrzel / NurPhoto via Getty Images Coca-Cola is ramping up production of high-protein milks. Key Takeaways Coca-Cola is leaning into its high-protein milk products,

(MedPage Today) — ORLANDO — Adding another twist to the ongoing debate about the effects of weight-loss drugs on vision, a retrospective cohort study linked

A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.

Glucagon-like peptide-1 (GLP-1) receptor agonists may support weight management in patients following bariatric surgery. A study suggests that GLP-1 drug use is particularly common among

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction

Ozempic may still be flying high in America, but not in American Airlines’ employee health plan. American Airlines Cuts Ozempic From Flight Attendant Healthcare Coverage

By Dennis Thompson HealthDay ReporterTUESDAY, Oct. 21, 2025 (HealthDay News) — Weight-loss drugs like Ozempic and Zepbound might help protect…

Key Points Though Novo Nordisk had a first-mover advantage in the GLP-1 market, Eli Lilly is catching up. Lilly’s recent clinical progress sets it up

Kara and Scott discuss more schools saying no to Trump’s college “compact,” the No Kings protests, and the AWS outage. Then, Trump’s promise to slash

A look at GLP-1 spend at medical aesthetics practices from 2021 to 2025, per data and analytics firm Guidepoint Qsight.

(MedPage Today) — In what some news reports dubbed “an awkward moment,” CMS Administrator Mehmet Oz, MD, stepped up to the podium in the Oval

(MedPage Today) — The FDA approved oral semaglutide (Rybelsus) to prevent major adverse cardiovascular events (MACE) in high-risk patients with diabetes, whether or not they’ve

Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive

MONDAY, Oct. 20, 2025 — Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially

American Airlines’ flight attendant union is expressing frustration over an upcoming change to the company’s healthcare plan, as flagged by PYOK. I’m curious to see

New data presented at AMWC Dubai highlights Sculptra’s regenerative effects and its synergy with Restylane to address GLP-1-related facial ageing. Discover expert insights and clinical

Post Content

As of Oct. 17, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

As GLP-1 weight-loss drugs like Ozempic reshape how consumers eat, food and beverage manufacturers are racing to develop precision nutrition solutions – using AI and

As the GLP-1 economy cools, CVS Ventures leads a $25 million round in Knownwell — betting on physician-led obesity care and payer-backed innovation.

Explore how functional ingredients are challenging GLP-1 drugs in weight management – and what this shift means for food and beverage innovation.

An estimated 100 million adult Americans—more than 40 percent of the population—are classified as obese. This is a massive health crisis that will claim many

Post Content